Home » Stocks » BPMC

Blueprint Medicines Corporation (BPMC)

Stock Price: $92.80 USD -5.99 (-6.06%)
Updated Mar 3, 2021 3:59 PM EST - Market closed
After-hours: $95.13 +2.33 (2.51%) Mar 3, 4:40 PM
Market Cap 5.67B
Revenue (ttm) 793.74M
Net Income (ttm) 313.88M
Shares Out 54.53M
EPS (ttm) 5.59
PE Ratio 16.60
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $92.80
Previous Close $98.79
Change ($) -5.99
Change (%) -6.06%
Day's Open 98.45
Day's Range 92.52 - 99.66
Day's Volume 412,598
52-Week Range 43.29 - 125.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.

Zacks Investment Research - 2 weeks ago

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.55% and -1.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...

Benzinga - 2 weeks ago

Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 13.33% over the past year to ($1.53), which beat the...

PRNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full ye...

PRNewsWire - 3 weeks ago

CAMBRIDGE, Mass., Feb. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...

Zacks Investment Research - 1 month ago

Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ...

Zacks Investment Research - 1 month ago

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

Other stocks mentioned: HALO, NVAX
PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company's research and development organization. E...

Zacks Investment Research - 1 month ago

We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.

Other stocks mentioned: HALO, MRNA
PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...

Zacks Investment Research - 2 months ago

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indic...

PRNewsWire - 2 months ago

CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...

Zacks Investment Research - 3 months ago

The FDA grants accelerated nod to Blueprint Medicines' (BPMC) Gavreto for treating patients with advanced/metastatic RET-altered thyroid cancer.

PRNewsWire - 3 months ago

CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...

The Motley Fool - 3 months ago

Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.

Other stocks mentioned: ADPT, BLUE, NVAX, RHHBY
Insider Monkey - 4 months ago

Keeping this in mind, let's analyze whether Blueprint Medicines Corporation (NASDAQ:BPMC) is a good investment right now by following the lead of some of the best investors in the world and pi...

PRNewsWire - 4 months ago

CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...

Seeking Alpha - 4 months ago

Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.

Zacks Investment Research - 4 months ago

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 71.96% and 31.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...

Insider Monkey - 4 months ago

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry exp...

Other stocks mentioned: ANAB, DRNA, QURE, SPRO
Zacks Investment Research - 5 months ago

Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.

Seeking Alpha - 5 months ago

Blueprint European Approval, And Other News: The Good, Bad And Ugly Of Biopharma

Zacks Investment Research - 5 months ago

Blueprint Medicines' (BPMC) Ayvakyt gains a conditional marketing approval from the European Commission for unresectable/metastatic gastrointestinal stromal tumors harboring the PDGFRA D842V m...

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 25, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer im...

Zacks Investment Research - 5 months ago

Blueprint Medicines (BPMC) reports positive top-line results from the EXPLORER and the PATHFINDER studies, which are evaluating Ayvakit for patients with advanced systemic mastocytosis. Shares...

Investors Business Daily - 5 months ago

Blueprint Medicines on Tuesday reported positive test results for its treatment for a potentially fatal rare disease, sending BPMC stock to an eight-month high extending beyond a buy zone. The...

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer im...

PRNewsWire - 5 months ago

PITTSBURGH, Sept. 14, 2020 /PRNewswire/ -- PANTHERx® Rare Pharmacy announces that it has been selected by Blueprint Medicines as a limited distribution partner for new drug GAVRETO™ (pralsetin...

The Motley Fool - 5 months ago

Here's what investors need to know about this successful yet underappreciated cancer drug developer.

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer imm...

Zacks Investment Research - 6 months ago

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 7 months ago

Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.

Seeking Alpha - 7 months ago

Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -9.62% and 10.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...

PRNewsWire - 7 months ago

CAMBRIDGE, Mass., July 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer imm...

CNBC Television - 7 months ago

Blueprint Medicines CEO on $1.7 billion cancer drug partnership with Roche

Blueprint Medicines has partnered with Roche on pralsetinib, a cancer drug.

Other stocks mentioned: RHHBY
The Motley Fool - 7 months ago

Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.

Other stocks mentioned: RHHBY
Zacks Investment Research - 7 months ago

Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.

Other stocks mentioned: RHHBY
24/7 Wall Street - 7 months ago

Blueprint Medicines Corp. (NASDAQ: BPMC) announced early on Tuesday that it had entered into a global collaboration with pharmaceutical giant Roche in which it may receive up to $1.7 billion.

Other stocks mentioned: RHHBY
Market Watch - 7 months ago

Shares of Blueprint Medicines Corp. BPMC, -2.93% gained 8.3% in premarket trading on Tuesday, the day after the company announced a deal with Roche Holding AG ROG, -1.66% to develop and commer...

Other stocks mentioned: RHHBY
PRNewsWire - 7 months ago

CAMBRIDGE, Mass., July 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer imm...

Other stocks mentioned: RHHBY
Zacks Investment Research - 8 months ago

Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock...

PRNewsWire - 8 months ago

CAMBRIDGE, Mass., July 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...

PRNewsWire - 8 months ago

CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer imm...

PRNewsWire - 8 months ago

CAMBRIDGE, Mass., June 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immu...

Zacks Investment Research - 8 months ago

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 9 months ago

Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.

Other stocks mentioned: DCPH
GuruFocus - 9 months ago

Andreas Halvorsen (Trades, Portfolio)’s Viking Global Investors bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.

Other stocks mentioned: AIZ, AVTR, BSX, CI, FTV, LIFE, V

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops transformative medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an o... [Read more...]

Industry
Biotechnology
IPO Date
Apr 30, 2015
CEO
Jeffrey Albers
Employees
429
Stock Exchange
NASDAQ
Ticker Symbol
BPMC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is 117.29, which is an increase of 26.39% from the latest price.

Price Target
$117.29
(26.39% upside)
Analyst Consensus: Buy